Marc Soudant

Mr. Marc Soudant

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2016 in The Lancet Neurology
Verified
Journal Article
Closed access
SBSerge Bracard
Serge Bracard
XDXavier Ducrocq
Xavier Ducrocq
JMJean Louis Mas
Jean Louis Mas
MSMarc Soudant
Marc Soudant
COCatherine Oppenheim
Catherine Oppenheim
FGFrancis Guillemin
Francis Guillemin

1 January 2019 in The Lancet Neurology
Verified
Journal Article
Closed access
DDDominique Deplanque
Dominique Deplanque
CMCharles B L M Majoie
Charles B L M Majoie
BMBijoy K Menon
Bijoy K Menon
YNYassi Nawaf
Yassi Nawaf
GSGagan Sharma
Gagan Sharma
JCJames Cunningham
James Cunningham

1 March 2019 in Stroke
Verified
Journal Article
Open access
PDF file
CPCorentin Provost
Corentin Provost
MSMarc Soudant
Marc Soudant
LLLaurence Legrand
Laurence Legrand
WHWagih Ben Hassen
Wagih Ben Hassen
YXYu Xie
Yu Xie
COCatherine Oppenheim
Catherine Oppenheim
Background and Purpose—: The acute management of stroke patients requires a fast and efficient screening imaging modality. We compared workflow and functional outcome in acute ischemic stroke patients screened by magnetic resonance imaging (MRI) or computed tomography (CT) before treatment in the THRACE trial (Thrombectomie des Artères Cérébrales), with the emphasis on the duration of the imaging step. Methods—: The THRACE randomized trial (June 2010 to February 2015) evaluated the efficacy of mechanical thrombectomy after intravenous tPA (tissue-type plasminogen activator) in ischemic stroke patients with proximal occlusion. The choice of screening imaging modality was left to each enrolling center. Differences between MRI and CT groups were assessed using univariable analysis and the impact of imaging modality on favorable 3-month functional outcome (modified Rankin Scale score of ≤2) was tested using multivariable logistic regression. Results—: Four hundred one patients were included (25 centers), comprising 299 MRI-selected and 102 CT-selected patients. Median baseline National Institutes of Health Stroke Scale score was 18 in both groups. MRI scan duration (median [interquartile range]) was longer than CT (MRI: 13 minutes [10–16]; CT: 9 minutes [7–12]; P <0.001). Stroke-onset-to-imaging time (MRI: median 114 minutes [interquartile range, 89–138]; CT: 107 minutes [88–139]; P =0.19), onset-to-intravenous tPA time (MRI: 150 minutes [124–179]; CT: 150 minutes [123–180]; P =0.38) and onset-to-angiography-suite time (MRI: 200 minutes [170–250]; CT: 213 minutes [180–246]; P =0.57) did not differ between groups. Imaging modality was not significantly associated with functional outcome in the multivariable analysis. Conclusions—: Although MRI scan duration is slightly longer than CT, MRI-based selection for acute ischemic stroke patients is accomplished within a timeframe similar to CT-based selection, without delaying treatment or impacting functional outcome. This should help to promote wider use of MRI, which has inherent imaging advantages over CT. Clinical Trial Registration—: URL: https://www.clinicaltrials.gov . Unique identifier: NCT01062698.

9 June 2020 in International Journal of Stroke
Verified
Journal Article
Closed access
PDF file
FZFrançois Zhu
François Zhu
GHGabriela Hossu
Gabriela Hossu
MSMarc Soudant
Marc Soudant
SRSébastien Richard
Sébastien Richard
HAHamza Achit
Hamza Achit
BGBenjamin Gory
Benjamin Gory
Background and hypothesis: There is no consensus on the optimal endovascular management of the extracranial internal carotid artery steno-occlusive lesion in patients with acute ischemic stroke due to tandem occlusion. We hypothesized that intracranial mechanical thrombectomy plus emergent internal carotid artery stenting (and at least one antiplatelet therapy) is superior to intracranial mechanical thrombectomy alone in patients with acute tandem occlusion. Study design: TITAN is an investigator-initiated, multicenter, prospective, randomized, open-label, blinded-endpoint (PROBE) study. Eligibility requires a diagnosis of acute ischemic stroke, pre-stroke modified Rankin Scale (mRS)≤2 (no upper age limit), National Institutes of Health Stroke Scale (NIHSS)≥6, Alberta Stroke Program Early Computed Tomography Score (ASPECTS)≥6, and tandem occlusion on the initial catheter angiogram. Tandem occlusion is defined as large vessel occlusion (intracranial internal carotid artery , M1 and/or M2 segment) and extracranial severe internal carotid artery stenosis ≥90% (NASCET) or complete occlusion. Patients are randomized in two balanced parallel groups (1:1) to receive either intracranial mechanical thrombectomy plus internal carotid artery stenting (and at least one antiplatelet therapy) or intracranial mechanical thrombectomy alone within 8 h of stroke onset. Up to 432 patients are randomized after tandem occlusion confirmation on angiogram. Study outcomes: The primary outcome measure is complete reperfusion rate at the end of endovascular procedure, assessed as a modified Thrombolysis in Cerebral Infarction (mTICI) 3, and ≥4 point decrease in NIHSS at 24 h. Secondary outcomes include infarct growth, recurrent clinical ischemic event in the ipsilateral carotid territory, type and dose of antiplatelet therapy used, mRS at 90 (±15) days and 12 (±1) months. Safety outcomes are procedural complications, stent patency, intracerebral hemorrhage, and death. Economics analysis includes health-related quality of life, and costs utility comparison, especially with the need or not of endarterectomy. Discussion: TITAN is the first randomized trial directly comparing two types of treatment in patients with acute ischemic stroke due to anterior circulation tandem occlusion, and especially assessing the safety and efficacy of emergent internal carotid artery stenting associated with at least one antiplatelet therapy in the acute phase of stroke reperfusion. Trial registration: ClinicalTrials.gov NCT03978988

1 October 2017 in Stroke
Verified
Journal Article
Closed access
PDF file
HAhamza ACHIT
hamza ACHIT
MSMarc Soudant
Marc Soudant
KHKossar Hosseini
Kossar Hosseini
ABAurélie Bannay
Aurélie Bannay
JEJonathan Epstein
Jonathan Epstein
FGFrancis Guillemin
Francis Guillemin
Background and Purpose—: The benefit of mechanical thrombectomy added to intravenous thrombolysis (IVT) in patients with acute ischemic stroke has been largely demonstrated. However, evidence of the economic incentive of this strategy is still limited, especially in the context of a randomized controlled trial. We aimed to analyze whether mechanical thrombectomy combined with IVT (IVMT) is cost-effective when compared with IVT alone. Methods—: Individual-level cost and outcome data were collected in the THRACE randomized controlled trial (Thrombectomie des Artères Cerébrales) including patients with acute ischemic stroke. Patients were assigned to receive IVT or IVMT. The primary outcomes were modified Rankin Scale score of functional independence at 90 days (score 0–2) and the EuroQol-5D quality-of-life score at 1 year. Results—: Treating acute ischemic stroke with IVMT (n=200) versus IVT (n=202) increased the rate of functional independence by 10.9% (53.0% versus 42.1%; P =0.028), at an increased cost of $2116 (€1909), with no significant difference in mortality (12% versus 13%; P =0.70) or symptomatic intracranial hemorrhage (2% versus 2%; P =0.71). The cost per one averted case of disability was estimated at $19 379 (€17 480). The incremental cost per one quality-adjusted life year gained was $14 881 (€13 423). On sensitivity analysis, the probability of cost-effectiveness with IVMT was 84.1% in terms of cases of averted disability and 92.2% in terms of quality-adjusted life years. Conclusions—: Based on randomized trial data, this study demonstrates that IVMT used to treat acute ischemic stroke is cost-effective when compared with IVT alone. Clinical Trial Registration—: URL: http://www.clinicaltrials.gov . Unique identifier: NCT01062698.

1 December 2014 in Radiology
Verified
Journal Article
Closed access
MCMichel Claudon
Michel Claudon
EDEmmanuel Durand
Emmanuel Durand
NGNicolas Grenier
Nicolas Grenier
APAlain Prigent
Alain Prigent
DBDaniel Balvay
Daniel Balvay
FGFor the DCE MR Urography Study Group
For the DCE MR Urography Study Group
To evaluate if measurement of split renal function ( SRF split renal function ) with dynamic contrast material-enhanced ( DCE dynamic contrast enhanced ) magnetic resonance (MR) urography is equivalent to that with renal scintigraphy ( RS renal scintigraphy ) in patients suspected of having chronic urinary obstruction. The study protocol was approved by the institutional ethics committee of the coordinating center on behalf of all participating centers. Informed consent was obtained from all adult patients or both parents of children. This prospective, comparative study included 369 pediatric and adult patients from 14 university hospitals who were suspected of having chronic or intermittent urinary obstruction, and data from 295 patients with complete data were used for analysis. SRF split renal function was measured by using the area under the curve and the Patlak-Rutland methods, including successive review by a senior and an expert reviewer and measurement of intra- and interobserver agreement for each technique. An equivalence test for mean SRF split renal function was conducted with an α of 5%. Reproducibility was substantial to almost perfect for both methods. Equivalence of DCE dynamic contrast enhanced MR urography and RS renal scintigraphy for measurement of SRF split renal function was shown in patients with moderately dilated kidneys (P < .001 with the Patlak-Rutland method). However, in severely dilated kidneys, the mean SRF split renal function measurement was underestimated by 4% when DCE dynamic contrast enhanced MR urography was used compared with that when RS renal scintigraphy was used. Age and type of MR imaging device had no significant effect. For moderately dilated kidneys, equivalence of DCE dynamic contrast enhanced MR urography to RS renal scintigraphy was shown, with a standard deviation of approximately 12% between the techniques, making substitution of DCE dynamic contrast enhanced MR urography for RS renal scintigraphy acceptable. For severely dilated kidneys, a mean underestimation of SRF split renal function of 4% should be expected with DCE dynamic contrast enhanced MR urography, making substitution questionable.